All In MedTech

FDA Clearance Tracker · P230032

AvertD and AvertD Buccal Sample Collection Kit

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Dec 19, 2023

Approved

Time to decision

85 days

Received Sep 25, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230032
Device name
AvertD and AvertD Buccal Sample Collection Kit
Applicant location
Carlsbad, CA
Received
Sep 25, 2023
Decided
Dec 19, 2023
Decision
Approved
Supplements
5 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QZH

FDA's approval statement

As written in FDA's record.

AvertD™ is a prescription, qualitative genotyping test used to detect and identify 15 genetic polymorphisms in genomic DNA isolated from buccal samples collected from individuals 18 years of age and older. The test may be used as part of a clinical evaluation and risk assessment to identify patients who may be at elevated risk for developing opioid use disorder (OUD). The test is indicated for use only in patients prior to receiving a first prescription of oral opioids for 4-30 days for acute pain, such as in patients scheduled to undergo a planned surgical procedure and who consent to having the test performed. The AvertD™ Buccal Sample Collection Kit is intended for use in the non-invasive collection, transport and storage of buccal specimens. DNA from the buccal sample will be suitable for use in AvertD. Buccal samples are collected by a qualified healthcare professional. For use only in individuals 18 years or older.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QZH (Opioid use disorder genetic risk variant detection system and collection kit).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for AutoGenomics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.